An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 323 participants.

Also called NCT07543120

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 323 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07543120
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Japan, Singapore (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07543120. Allocation not applicable; no masking; primary purpose treatment. Start 2026-05-07 (actual); primary completion 2031-05-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Condition
Hypertension (HTN)
Intervention (Drug)
QCZ484
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07543120
Content hash
5801eef701a0ac4edb21550bc0874b03115afc160158bbcb295585f6bc2fabc2